Teva: Our Biosimilars Strategy Has Been Fragmented, We Want To Be Global
Israeli Firm ‘Absolutely’ Believes Biosimilars Are Long-Term Growth Driver
Months into the job, Teva CEO Richard Francis delivered the company’s promise for a new dedicated strategy to return to growth. Funded by a portion of capital reallocated from Teva’s generics business to focus on innovative brands, the new strategy will continue to promote biosimilars, Teva has outlined.
You may also be interested in...
Teva has celebrated a US nod for its generic version of Forteo, the first substitutable teriparatide rival to be approved by the US Food and Drug Administration.
Teva management sounded an optimistic note as the firm delivered its third-quarter results for 2023, adding a further $100m to the company’s full-year sales forecast and providing updates on a number of key aspects of the business.
Samsung Bioepis has reported positive Phase I and Phase III trial results for its SB16 proposed denosumab biosimilar to Prolia.